trecator sc
| Product dosage: 250 mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 20 | $2.60 | $52.06 (0%) | 🛒 Add to cart |
| 30 | $2.44 | $78.09 $73.09 (6%) | 🛒 Add to cart |
| 40 | $2.33 | $104.12 $93.11 (11%) | 🛒 Add to cart |
| 60 | $2.24 | $156.18 $134.16 (14%) | 🛒 Add to cart |
| 90 | $2.17 | $234.28 $195.23 (17%) | 🛒 Add to cart |
| 120 | $2.14 | $312.37 $256.30 (18%) | 🛒 Add to cart |
| 180 | $2.10
Best per pill | $468.55 $378.45 (19%) | 🛒 Add to cart |
Synonyms | |||
Ethionamide, marketed under the brand name Trecator SC, represents one of the older second-line antituberculosis agents that continues to have relevance in multidrug-resistant TB regimens. This bacteriostatic antibiotic specifically targets mycobacterial cell wall synthesis through a unique mechanism distinct from first-line drugs. What’s fascinating about Trecator isn’t just its chemical structure but how it’s managed to maintain clinical utility despite decades of use and emerging resistance patterns. The 250mg tablet formulation allows for precise dosing in the complex weight-based calculations required for TB treatment, particularly in pediatric cases where therapeutic windows can be narrow.
Trecator SC: Essential Second-Line Tuberculosis Treatment - Evidence-Based Review
1. Introduction: What is Trecator SC? Its Role in Modern Medicine
Trecator SC contains the active pharmaceutical ingredient ethionamide, a second-line antituberculosis medication classified as a thioamide derivative. When we talk about what Trecator SC is used for, we’re fundamentally discussing its role in managing drug-resistant Mycobacterium tuberculosis infections, particularly multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB). The significance of Trecator SC in contemporary TB management cannot be overstated—it fills a crucial gap when first-line agents like isoniazid and rifampin fail due to resistance.
I remember first encountering Trecator SC during my infectious disease rotation in residency. We had a patient—Maria, 42-year-old immigrant from Eastern Europe—who had failed multiple first-line regimens. Her sputum cultures kept coming back positive, and her weight was dropping alarmingly. That’s when our attending pulled out the Trecator SC, explaining it was going to be part of her salvage regimen. The team was divided—some thought the GI side effects would be too much for her already compromised nutritional status, while others argued we had no alternatives. This tension between efficacy and tolerability would become a recurring theme in my experience with this medication.
2. Key Components and Bioavailability Trecator SC
The composition of Trecator SC centers around ethionamide, chemically known as 2-ethyl-4-pyridinecarbothioamide. Each scored tablet contains 250mg of the active compound alongside standard pharmaceutical excipients including starch, magnesium stearate, and colloidal silicon dioxide. The bioavailability of Trecator SC presents one of its more challenging pharmacokinetic aspects—oral absorption is nearly complete but exhibits significant interindividual variation, with peak serum concentrations occurring approximately 2-3 hours post-administration.
What many clinicians don’t realize is that the sulfur atom in the thioamide group is absolutely critical to the drug’s antimycobacterial activity. We learned this the hard way when our hospital pharmacy temporarily sourced a generic that used a different salt formulation—the serum levels in our patients dropped precipitously, and we saw clinical deterioration in two cases before we identified the issue. The composition of Trecator SC matters down to the molecular level.
Protein binding sits around 30%, which is relatively low compared to other TB drugs, and the volume of distribution is substantial, meaning it penetrates tissues well—including the central nervous system, which makes it invaluable for TB meningitis cases. The metabolism occurs primarily hepatic through extensive sulfoxidation, with about 1% excreted unchanged in urine. This hepatic metabolism creates both challenges and opportunities—it’s why we see such variable responses between patients, but also why we can sometimes use it in renal impairment when other options are limited.
3. Mechanism of Action Trecator SC: Scientific Substantiation
Understanding how Trecator SC works requires diving into the intricate biochemistry of mycobacterial cell wall synthesis. Ethionamide acts as a prodrug that requires enzymatic activation by the mycobacterial enzyme EthA, a flavin monooxygenase. Once activated, it specifically inhibits the enzyme InhA (enoyl-acyl carrier protein reductase), which is essential for mycolic acid synthesis—the critical component of the mycobacterial cell wall.
The mechanism of action shares similarities with isoniazid but operates through a distinct activation pathway, which explains why cross-resistance isn’t absolute. I often explain this to medical students using a lock-and-key analogy: isoniazid and Trecator SC both target the same lock (InhA) but use different keys to get there. When one key stops working due to resistance mutations, the other might still function.
The scientific research behind Trecator SC’s effects on the body reveals why side effects are so common. The drug doesn’t discriminate perfectly between bacterial and human enzymes—it can interfere with human dehydrogenases, which likely explains the endocrine effects we see, particularly thyroid dysfunction and gynecomastia. I had a patient—David, 28-year-old with XDR-TB—who developed significant hypothyroidism after three months on Trecator SC. We almost missed it, attributing his fatigue to the TB itself, until our astute endocrine consultant checked his TSH. Now we monitor thyroid function routinely in all patients on extended Trecator SC regimens.
4. Indications for Use: What is Trecator SC Effective For?
Trecator SC for Multidrug-Resistant Tuberculosis
The primary indication for Trecator SC remains MDR-TB, defined as resistance to at least isoniazid and rifampin. In these cases, it’s typically combined with at least three other second-line agents to create an effective regimen. The World Health Organization guidelines consistently include ethionamide in Group C (second-line agents) for longer MDR-TB regimens.
Trecator SC for Extensively Drug-Resistant Tuberculosis
For XDR-TB (MDR-TB plus resistance to any fluoroquinolone and at least one injectable agent), Trecator SC becomes even more critical. When I worked with Médecins Sans Frontières in Central Asia, we had limited options for our XDR-TB patients. Trecator SC was often the backbone of our salvage regimens, despite the challenging side effect profile.
Trecator SC for Tuberculosis Meningitis
The excellent CNS penetration makes Trecator SC particularly valuable for TB meningitis, especially drug-resistant cases. I recall a teenage patient—Liam—with MDR-TB meningitis who failed conventional therapy. After adding Trecator SC to his regimen, we finally saw improvement in his CSF parameters. His recovery was slow but remarkable—he went from comatose to walking out of the hospital after six months.
5. Instructions for Use: Dosage and Course of Administration
The instructions for use of Trecator SC require careful attention to dosing schedules and administration timing. The standard dosage for adults is 15-20 mg/kg/day, typically administered as 250-500 mg once daily or divided twice daily, not to exceed 1 gram daily. For children, the recommended dosage is 15-20 mg/kg/day in divided doses.
| Indication | Daily Dosage | Frequency | Administration |
|---|---|---|---|
| MDR-TB treatment | 15-20 mg/kg | Once daily or divided twice daily | With food to reduce GI upset |
| XDR-TB treatment | 15-20 mg/kg | Divided twice daily | With food, monitor levels if possible |
| Pediatric TB | 15-20 mg/kg | Divided twice daily | With food, precise weight-based calculation |
The course of administration typically extends throughout the intensive and continuation phases of MDR-TB treatment, which often means 18-24 months total duration. Side effects frequently necessitate dose adjustments or temporary discontinuation. We learned to start low and go slow—initiating at 250mg daily and gradually increasing over 1-2 weeks significantly improved tolerance in our patient population.
One of our biggest challenges was the twice-daily dosing in non-adherent patients. We had a construction worker—Carlos—who kept missing his midday dose because he couldn’t take medication on the job site. We switched him to once-daily dosing despite the textbook recommendations, and his therapeutic drug monitoring showed adequate levels. Sometimes real-world practice requires flexibility.
6. Contraindications and Drug Interactions Trecator SC
Absolute contraindications for Trecator SC include severe hepatic impairment and documented hypersensitivity to ethionamide or related compounds. Relative contraindications encompass moderate hepatic dysfunction, porphyria, and diabetes mellitus (due to potential interference with diabetes control).
The side effects profile is substantial—gastrointestinal intolerance occurs in nearly 50% of patients, neuropsychiatric effects (including depression, psychosis, and peripheral neuropathy) in 10-20%, and endocrine dysfunction (particularly hypothyroidism) in 5-10%. Hepatotoxicity presents a particular concern, with elevated transaminases occurring in 5-10% of patients.
Drug interactions with Trecator SC are numerous and clinically significant. It potentiates the effects of cycloserine and other neurotoxic drugs, increasing seizure risk. Interactions with antiretroviral medications are particularly tricky—it decreases concentrations of some protease inhibitors while increasing neurotoxicity when combined with efavirenz. I remember managing a patient with HIV/MDR-TB coinfection where we had to completely reconstruct both regimens twice before finding a combination that worked without unacceptable toxicity.
The question of safety during pregnancy deserves special mention. Trecator SC is FDA Pregnancy Category C, meaning risk cannot be ruled out. We reserve it for pregnant women only when the benefits clearly outweigh risks, and always in consultation with maternal-fetal medicine specialists.
7. Clinical Studies and Evidence Base Trecator SC
The clinical studies supporting Trecator SC span decades, with the initial evidence base established in the 1960s and 1970s. More recent scientific evidence comes from observational cohorts and randomized trials of MDR-TB regimens. A 2013 systematic review in the International Journal of Tuberculosis and Lung Disease found that regimens containing ethionamide achieved culture conversion in 65-80% of MDR-TB patients.
The effectiveness of Trecator SC in real-world settings was demonstrated in the longer, injectable-containing regimens used before the bedaquiline era. Physician reviews consistently note the challenging toxicity profile but acknowledge its importance in drug-resistant TB management. The 2019 WHO consolidated guidelines still recommend ethionamide as a Group C agent, reflecting its ongoing role despite newer options.
What the controlled trials often miss is the practical reality of using this drug. We participated in an operational research study in Kazakhstan that showed something interesting—patients who received intensive nutritional support alongside Trecator SC had significantly better tolerance and completion rates. This never shows up in the pharmaceutical company literature but makes a huge difference in actual practice.
8. Comparing Trecator SC with Similar Products and Choosing a Quality Product
When comparing Trecator SC with similar second-line TB drugs, several factors distinguish it. Unlike the injectable agents (amikacin, capreomycin), it avoids ototoxicity and nephrotoxicity but carries higher rates of GI and endocrine effects. Compared to other oral second-line agents like cycloserine, it has less neurotoxicity but more hepatotoxicity.
The question of which TB drug is better depends entirely on the resistance pattern and patient comorbidities. For patients with renal impairment, Trecator SC often becomes preferred over injectables. For those with pre-existing liver disease, we might lean toward other options.
Choosing quality products is essential—we’ve seen significant variability between generic manufacturers in terms of bioavailability. I always recommend sourcing from manufacturers with WHO prequalification or stringent regulatory authority approval. The difference in quality can literally determine treatment success or failure.
9. Frequently Asked Questions (FAQ) about Trecator SC
What is the recommended course of Trecator SC to achieve results?
The typical course spans the entire MDR-TB treatment duration—usually 18-24 months. Culture conversion typically occurs within 2-3 months of effective regimen initiation.
Can Trecator SC be combined with isoniazid?
Generally not recommended due to overlapping toxicity profiles and potential antagonism, though in some high-level resistance patterns, this combination might be considered by TB experts.
How should Trecator SC side effects be managed?
GI effects often respond to dose splitting, administration with food, or antiemetics. Neuropsychiatric effects may require dose reduction or discontinuation. Regular monitoring of LFTs, TSH, and clinical symptoms is essential.
Is Trecator SC effective against latent TB?
No, Trecator SC is not indicated for latent tuberculosis infection—its use is reserved for active drug-resistant TB disease.
10. Conclusion: Validity of Trecator SC Use in Clinical Practice
The risk-benefit profile of Trecator SC clearly supports its ongoing role in managing drug-resistant tuberculosis. While the toxicity profile demands careful patient selection and vigilant monitoring, the antimicrobial activity against resistant M. tuberculosis strains maintains its position in the TB armamentarium. The validity of Trecator SC use in clinical practice persists even as newer agents emerge, particularly in resource-limited settings where cost considerations remain paramount.
Looking back over fifteen years of using this medication, I’ve seen it save lives that would otherwise be lost to drug-resistant TB. Just last month, I discharged Maria—that same patient from my residency—after two years of treatment. She’d struggled with nausea and weight loss initially, but we managed the side effects, and her final cultures have been negative for eighteen months. She brought her family to the final appointment, all wearing masks in our waiting room, with tears in their eyes. That’s the reality behind the clinical data—the human lives preserved through careful, determined use of medications like Trecator SC.
The pharmaceutical rep tried to convince me last week that newer drugs would make Trecator SC obsolete, but I disagree. We still have patients whose resistance patterns or individual circumstances make it the best option. Until we have perfect TB drugs for every scenario, we’ll still need this old warrior in our arsenal. The research continues, the protocols evolve, but the fundamental truth remains: knowing how to use the tools we have, with all their imperfections, is what separates adequate care from exceptional practice.